Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 11/20 | 0.76 |
| ▸ | HTR2B | P41595 | 3/20 | 0.76 |
| ▸ | HTR1D | P28221 | 3/20 | 0.76 |
| ▸ | HTR1A | P08908 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | HTR1B | P28222 | 2/20 | 0.76 |
| ▸ | HTR7 | P34969 | 2/20 | 0.76 |
| ▸ | HTR6 | P50406 | 2/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.76 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.76 |
| ▸ | HTR3B | O95264 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | HTR1E | P28566 | 1/20 | 0.76 |
| ▸ | HTR1F | P30939 | 1/20 | 0.76 |
| ▸ | DRD3 | P35462 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serotonin SCHEMBL1495 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL183226 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL29349412 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL30057954 | 0.86 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL25341783 | 0.85 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL396997 | 0.85 | HTR2C (0.97) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL1675866 | 0.85 | HTR2C (0.97) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL8208967 | 0.85 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL3091827 | 0.85 | HTR2C (0.97) | HTR2CHTR2AHTR2BHTR1DHTR1A | |
| Serotonin SCHEMBL29669289 | 0.85 | HTR2C (0.97) | HTR2CHTR2AHTR2BHTR1DHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| EP-0736770-A2 | An immunoreactive conjugate, method for its preparation, antibodies to said conjugate and a pharmaceutical composition and diagnostic device containing them | ANDA BIOLOGICALS S.A. (FR) | 1996-10-09 | — | — | EP | claimed |
| US-20240417764-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY | 2024-12-19 | — | — | US | disclosed |
| EP-4426676-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | METACEN THERAPEUTICS (KR) | 2024-04-18 | — | — | US | disclosed |
| EP-4353227-A1 | COMPOSITION INCLUDING INDOLE DERIVATIVE FOR PREVENTION OF ADVANCED GLYCATION END PRODUCT-RELATED DISEASE | Metacen Therapeutics (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023125404-A1 | SPINAL CORD INJURY TARGETED DRUG, POLYMER-HYDROPHOBIC COMPOUND MICELLE, AND PREPARATION METHOD FOR SPINAL CORD INJURY TARGETED DRUG | 浙江大学 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023081837-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20030105318-A1 | DNA encoding SNORF33 receptor | SYNPATIC PHARMACEUTICAL CORPORATION | 2003-06-05 | — | — | US | disclosed |
| EP-1100896-A4 | DNA ENCODING SNORF33 RECEPTOR | SYNAPTIC PHARMA CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2003-02-27 | — | — | US | disclosed |
| EP-1100896-A1 | DNA ENCODING SNORF33 RECEPTOR | Synaptic Pharmaceutical Corporation (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000073449-A1 | DNA ENCODING SNORF33 RECEPTOR | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-0736770-A2 | An immunoreactive conjugate, method for its preparation, antibodies to said conjugate and a pharmaceutical composition and diagnostic device containing them | ANDA BIOLOGICALS S.A. (FR) | 1996-10-09 | — | — | EP | disclosed |
| EP-0000322-A1 | Compounds having an anti-depressive or tranquilizing activity, pharmaceutical compositions containing them, and processes and intermediates for their preparation | Astra Läkemedel Aktiebolag (SE) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | AGER, IDO1, IAPP | HTR2C 611/4885HTR2A 339/4885HTR2B 1318/4885 |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | DCK, CCR1, CCNT1 | HTR2C 503/4885HTR2A 1693/4885HTR2B 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.